###begin article-title 0
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 246 255 246 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 335 340 335 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53)</italic>
###xml 428 432 428 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 504 509 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
Although postoperative chemotherapy is widely accepted as the standard modality for Dukes' stage C or earlier stage colorectal cancer (CRC) patients, biomarkers to predict those who may benefit from the therapy have not been identified. Previous in vitro and clinical investigations reported that CRC patients with wild-type p53 gene (TP53)-tumors benefit from 5-fluorouracil (5-FU) based chemotherapy, while those with mutated TP53-tumors do not. However, these studies evaluated the mutation-status of TP53 by immunohistochemistry with or without single-strand conformation polymorphism, and the mutation frequency was different from study to study. In addition, the polymorphic status at p53 codon 72, which results in arginine or proline residues (R72P) and is thought to influence the function of the protein significantly, was not examined.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 104 112 <span type="species:ncbi:9606">patients</span>
To evaluate the significance of the TP53 mutation as a molecular marker to predict the prognosis of CRC patients, especially those who received postoperative chemotherapy, we examined the mutation by direct sequencing from fresh CRC tumors and evaluated the R72P polymorphism of the mutated TP53 by a combined mutant allele- and polymorphic allele-specific polymerase chain reaction (PCR).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 457 461 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 502 511 502 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p = 0.012</italic>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 297 305 <span type="species:ncbi:9606">patients</span>
The TP53 mutation occurred in 147 (70%) of 211 Japanese CRC tumors. The mutation was observed in 93 (63%) tumors on the R72 allele and in 54 (37%) tumors on the P72 allele. Although the alterations to TP53 have no prognostic significance for CRC patients overall, we found that Dukes' stage C CRC patients who did not receive postoperative chemotherapy and carried the mutated TP53-R72 showed significantly longer survival times than those with the mutated TP53-P72 when evaluated by overall survival (p = 0.012).
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 119 124 119 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
Using a combined mutant allele- and polymorphic allele-specific PCR, we defined the codon 72 polymorphic status of the TP53 mutated allele in Japanese CRC patients. We raised a possibility that Dukes' stage C colorectal cancer patients with tumors carrying TP53 mutation, especially the P72 allele, benefited from 5-FU based postoperative chemotherapy.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 314 319 314 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 563 568 563 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 991 992 987 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 993 994 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1298 1300 1294 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1301 1303 1297 1299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 268 273 <span type="species:ncbi:9606">human</span>
###xml 1288 1296 <span type="species:ncbi:9606">patients</span>
The tumor suppressor, p53, has a central role in stress responses that induce cell cycle arrest, senescence, apoptosis or DNA repair, and preserve genomic stability [1-6]. Therefore, dysfunction of the p53 pathway is a hallmark of neoplasms. Approximately half of all human tumors carry an alteration of the gene, TP53 [7]. Alterations of TP53 play a significant role in the progression of colorectal cancer (CRC) and may be a clinically useful molecular marker of prognosis or response to treatments such as chemotherapy, radiotherapy or combination of the two. TP53 is unique among tumor suppressor genes because its alteration not only results in loss-of-function of the product, but also generates a range of mutants demonstrating a gain-of-function phenotype. Li et al. and Blandino et al. reported that the expression of selected p53 mutants inhibited p53-independent apoptosis induced by the gamma-irradiation and the anticancer reagents such as doxorubicin, cisplatin and etoposide [8,9]. Thereafter, in the last 10 years, the gain-of-function p53 mutants have been under intensive investigation because understanding the precise molecular mechanisms may provide information for personalized management and create promising therapeutic targets to benefit a large number of cancer patients [10,11].
###end p 10
###begin p 11
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 645 647 645 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 854 856 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 941 943 941 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 530 535 <span type="species:ncbi:9606">human</span>
###xml 1061 1069 <span type="species:ncbi:9606">patients</span>
More than 200 single nucleotide polymorphisms (SNPs) have been identified for TP53, 19 of which are exonic. Eleven of the exonic SNPs are non-synonymous resulting in an exchange of coding amino acid residues [10]. One of these SNPs results in either arginine (R) or proline (P) residues at codon 72 (R72P, rs1042522). A decade ago, this SNP gained attention when Storey et al. reported that the wild-type p53 with an arginine residue at codon 72 (hereafter p53-R72) is efficiently degraded by the E6 protein of the oncogenic type human papilloma viruses (HPV) and that p53-R72 homozygotes are at risk for HPV-associated uterine cervical cancer [12]. In contrast, later reports demonstrated that p53 with a proline residue at codon 72 (hereafter p53-P72) is associated with an increased risk in lung, esophagus, breast, urothelial and colorectal cancers [13-18]. However, other studies did not find any association with colorectal cancer [19,20]. The significance of the polymorphism R72P in association with the risk of cancer development or outcomes of cancer patients remains inconclusive, possibly due to differences in ethnic groups, genetic heterogeneity, sample number, cancer types, and treatment modalities in the each investigated cancer and population.
###end p 11
###begin p 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 611 613 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 631 639 631 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 832 837 832 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 871 879 <span type="species:ncbi:9606">patients</span>
TP53 mutation in combination with the codon 72 polymorphic status has been examined extensively. Selected p53 mutants have been shown to gain the ability to bind to p73, a homologue of p53, and to inactivate the apoptosis pathway mediated by p73. Interestingly, this gain-of-function mutation is influenced by the p53 codon 72 polymorphism, and the mutated p53-R72 bind p73 more efficiently than the mutated p53-P72 [21]. As a result, the mutated p53-R72 show an enhanced dominant negative influence on the p73L/p73 pathway [22,23] and a significantly decreased response to cytotoxic chemotherapeutic reagents [24]. Although these in vitro-findings are partly supported by clinical investigations in several kinds of cancers [25-27], it is not yet addressed in CRC. Thus, in this study, we examined the polymorphism R72P of mutated TP53 in relation to the outcome of CRC patients who was received postoperative chemotherapy.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
Patient population and tissue specimens
###end title 14
###begin p 15
###xml 611 612 605 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 785 787 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 876 878 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 52 55 <span type="species:ncbi:9606">men</span>
###xml 63 68 <span type="species:ncbi:9606">women</span>
###xml 303 310 <span type="species:ncbi:9606">Patient</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 560 568 <span type="species:ncbi:9606">patients</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
###xml 1035 1043 <span type="species:ncbi:9606">patients</span>
###xml 1286 1294 <span type="species:ncbi:9606">patients</span>
###xml 1535 1543 <span type="species:ncbi:9606">patients</span>
###xml 1545 1553 <span type="species:ncbi:9606">Patients</span>
###xml 1665 1672 <span type="species:ncbi:9606">patient</span>
The study population consisted of 212 patients (122 men and 90 women; mean age 64.5 years) who had surgical resection of sporadic colorectal cancers during the period from 2002 to 2004 at Kanagawa Cancer Center Hospital. Cancer tissues were obtained from each case, and stored at -80degreesC until use. Patient outcome was followed either until their death or until July 31, 2008, and all the survival data of this study was restricted to 157 patients who passed at least 4 years after the operation. Demographic and clinicopathological characteristics of the patients included in the study are listed in Table 1. Pathologic stage was determined using the Dukes' staging system. Histopathologic types were described according to the World Health Organization Classification of Tumors [28]. Differentiation of adenocarcinomas was evaluated according to the TNM classification [29]. The number of lymph node metastases of advanced cancer patients was evaluated from pathological reports in at least 12 dissected lymph nodes. Ninety-four patients received postoperative chemotherapy. The 5-FU-based regimens included tegafur and uracil (UFT) following 5-FU: leucovorin (LV)/5-FU (RPMI regimen), 28 cases; LV/5-FU/CPT-11 (FOLFIRI/IFL), 11 cases; LV/UFT-based regimens, 55 cases. Twenty-six patients with Dukes' stage C did not agree to undergoing postoperative chemotherapy. The present study was approved by the institutional ethical review board at Kanagawa Cancer Center, and written informed consent to the study was obtained from all patients. Patients' follow-up data were obtained through a review of hospital and physician's records, by direct contact with the patient or through the social residential registration.
###end p 15
###begin p 16
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Histological and clinical features of colorectal cancer patients (n = 212)
###end p 16
###begin p 17
SD, standard deviation.
###end p 17
###begin title 18
Nucleic acid preparation and cDNA synthesis
###end title 18
###begin p 19
###xml 178 182 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
###xml 311 317 309 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12-18 </sub>
###xml 343 347 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
Genomic DNA was isolated from tumor tissues using the QIAamp DNA Mini Kit (Qiagen KK, Tokyo, Japan) according to the manufacture's instructions. RNA was extracted with the TRIZOL(R) Reagent (Invitrogen, Carlsbad, CA), following the manufacture's instructions. First-strand cDNA was synthesized with an oligo(dT)12-18 primer and the SuperScript(R) First-Strand Synthesis System for RT-PCR (Invitrogen).
###end p 19
###begin title 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
TP53 mutation analysis
###end title 20
###begin p 21
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 95 100 95 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 469 474 451 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 563 568 545 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
Mutational analysis of TP53 was performed by direct sequencing. Briefly, a 1.64 kb fragment of TP53 (corresponding to exons 5-8) was amplified from genomic DNA extracted from each tumor by polymerase chain reaction (PCR). The PCR products were purified and directly sequenced using GenomeLabtrade mark DTCS Quick Start Kit and the CEQtrade mark 2000XL DNA Analysis System (Beckman Coulter, Inc., Fullerton, CA). The obtained nucleotide sequences were compared with the TP53 reference sequence (GenBank accession number ). The primers used to amplify exons 5-8 of TP53 are available on request.
###end p 21
###begin title 22
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
Determination of the TP53 codon 72 polymorphic status of tumors
###end title 22
###begin p 23
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
For the determination of polymorphism at codon 72 of TP53, an allele-specific PCR assay was used as described previously [12,30] with minor modifications. The precise information for PCR conditions is provided in Additional file 1.
###end p 23
###begin p 24
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 836 837 836 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
For the TP53 mutated tumors with arginine/proline heterogeneous polymorphic status at codon 72, a combined method of the polymorphic allele-specific [31] and the mutant allele-specific [32] PCR was performed to determine whether the TP53 mutation occurred on the arginine allele or on the proline allele. Briefly, the method was designed to place the polymorphic nucleotides at the 3'-end of the forward primers and the mutated sites at the 3'-end of the reverse primers. The nucleotide sequences of the two polymorphic allele specific primers were 5'-gaggctgctccccg-3' for the arginine allele and 5'-gaggctgctccccc-3' for the proline allele. The nucleotide sequences of the reverse primers, specific to each mutation site, are listed in Additional file 2. The precise information for PCR conditions is also provided in Additional file 1.
###end p 24
###begin title 25
Statistical Methods
###end title 25
###begin p 26
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
The relationship between the codon 72 polymorphic status of the mutated allele of TP53 and individual clinicopathological variables were assessed using chi-square tests. Overall survival curves were generated by Kaplan-Meier analysis, and the log rank test was used to compare between survival curves. Differences were considered significant when a P value < 0.05 was obtained. All the statistic analyses were performed by SPSS version 15 for Windows (SPSS Inc. Chicago, IL).
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
TP53 codon 72 polymorphic status of the tumors
###end title 28
###begin p 29
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1a</xref>
###xml 364 371 <span type="species:ncbi:9606">patient</span>
We analyzed the polymorphic status of the TP53 codon 72 by allele-specific PCR analysis. As shown in Table 2, the allele frequencies were determined as 42% (89 tumors) for the arginine allele, 45% (94 tumors) for the heterozygous arginine/proline status, and 13% (28 tumors) for the proline allele, respectively. There was no significant difference in the overall patient survival among the three codon 72 status groups as assessed by the Kaplan-Meier analysis (Figure 1a).
###end p 29
###begin p 30
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Genotype frequencies at codon 72 of TP53 in colorectal cancer patients (n = 211)
###end p 30
###begin p 31
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effect of <italic>TP53 </italic>codon 72 genotype on overall survival in colorectal cancer patients</bold>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 414 419 414 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
###xml 400 408 <span type="species:ncbi:9606">patients</span>
Effect of TP53 codon 72 genotype on overall survival in colorectal cancer patients. (a): The association between the TP53 codon 72 genotype and overall survival. (b): Overall survival with TP53 mutation on the Arg allele and Pro allele (n = 109. P = 0.120). (c): Overall survival in heterozygous patients with TP53 mutation (n = 46, P = 0.056). (d): Overall survival in homo- and hemizygous genotype patients with TP53 mutation (n = 63, P = 0.688).
###end p 31
###begin title 32
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
TP53 mutations of the tumors
###end title 32
###begin p 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 136 141 136 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S3">3</xref>
###xml 348 349 348 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S4">4</xref>
###xml 659 663 659 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 924 929 924 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 55 62 <span type="species:ncbi:9606">patient</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
TP53 mutation occurred in 148 (70%) of the tumors. One patient with tumors heterozygous for the codon 72 polymorphism had two different TP53 mutations on each allele. Therefore, we removed this case and used 211 patients for the following analyses (Table 2). Individual mutations in detail and the codon 72 allelism are shown in Additional file 3, 4. Briefly, we found 107 missense (73%), 8 frameshift (5%), 9 splice (6%), 17 nonsense (12%), 2 missense+nonsense (1%) and 4 other mutations. Silent mutation was considered as wild-type in the present study for analyses. Eleven non-synonymous polymorphisms, including the codon 72 (R72P), are now recognized in TP53. We evaluated 5 polymorphic sites except for R72P located in exons 5-8, including V217 M, R267W, P278A, R290H and N311S [10], respectively. In the present study, all the examined sequences corresponding to the above polymorphic sites matched completely to the TP53 reference sequence used, and no exonic non-synonymous polymorphism other than R72P was observed.
###end p 33
###begin title 34
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 51 58 <span type="species:ncbi:9606">patient</span>
TP53 codon 72 status with or without mutations and patient outcome
###end title 34
###begin p 35
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 398 399 398 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 465 470 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 513 514 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 742 746 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 783 787 783 787 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 916 921 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 946 951 946 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1b</xref>
###xml 1045 1050 1045 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 1078 1083 1078 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 1117 1121 1117 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1145 1149 1145 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1226 1231 1226 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1402 1406 1402 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1462 1467 1462 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 1519 1521 1519 1521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1c</xref>
###xml 1626 1630 1626 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1665 1669 1665 1669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1902 1906 1902 1906 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1927 1931 1927 1931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1944 1946 1944 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1d</xref>
###xml 890 898 <span type="species:ncbi:9606">patients</span>
###xml 1346 1353 <span type="species:ncbi:9606">patient</span>
###xml 1575 1582 <span type="species:ncbi:9606">patient</span>
###xml 1600 1608 <span type="species:ncbi:9606">patients</span>
###xml 1639 1647 <span type="species:ncbi:9606">patients</span>
###xml 1849 1856 <span type="species:ncbi:9606">patient</span>
We determined TP53 mutated allele for the 62 tumors heterozygous for the codon 72 polymorphic status. Twenty-six TP53 mutations occurred on the arginine allele and 36 mutations occurred on the proline allele (Table 2). In total, TP53 mutation occurred on the arginine allele in 93 tumors (44%) and on the proline allele in 54 tumors (26%) among the 211 informative colorectal cancer samples (Table 3). The lymph node metastasis was significantly increased with the TP53 mutation (p < 0.05, chi-square test; Table 3). However, the background factors of age, sex, number of lymph node metastasis, tumor size, metastasis, venous involvement and lymphatic involvement were not statistically different between the tumors consisting of the mutated TP53-R72 and the tumors with the mutated TP53-P72 (data not shown). Likewise, there were no significant differences in the overall survival between patients with the mutated TP53-R72 and with the mutated TP53-P72 (Figure 1b). In the present analysis, we were not able to distinguish tumors with mutated TP53-R72 together with wild-type TP53-R72 from tumors lacking wild-type TP53-R72 by LOH. Concerning TP53-P72, the findings were the same. Therefore, we selected tumors with mutated TP53 under heterozygous codon 72 status, a definitive retention of the other wild-type allele, and analyzed the overall patient survival. There was a tendency that the mutated TP53-P72 showed a poorer prognosis than that of the mutated TP53-R72, but the difference was not significant (Figure 1c). There was no significant difference in the overall patient survival between patients with the mutated TP53-R72 and patients with the mutated TP53-P72 under homozygous codon 72 status, which includes both LOH tumors and tumors retaining the homologous wild-type allele. There was also no significant difference in the overall patient survival between the tumors with the mutated TP53-R72 and the mutated TP53-P72 (Figure 1d).
###end p 35
###begin p 36
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
TP53 mutation and allelism (n = 211)
###end p 36
###begin p 37
* The statistical difference is shown by the chi-square test.
###end p 37
###begin title 38
Significance of the codon 72 status on the clinicopathological factors
###end title 38
###begin p 39
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
The CRC specimens were stratified by the location (colon or rectum), the histological subclasses and the Dukes' stage (Table 2). The frequency of mutation that occurred on the TP53-R72 or -P72 was not statistically different in tumor location or histological subclass (Table 3).
###end p 39
###begin p 40
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 356 360 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
The TP53 mutation rate showed a tendency to increase with the Dukes' stage progression to stage C. The TP53 mutation was 55% (23 out of 42) in Dukes' stage A patients and 84% (63 out of 75) in stage C patients, and this difference was statistically significant (p < 0.05, chi-square test; Table 3). However, frequency of the mutations that occurred on the TP53-R72 or -P72 and the Dukes' stage showed no significant relevance (p > 0.05, chi-square test). In addition, the overall survival of the patients was not different between the mutated alleles and the Dukes' stages (data not shown).
###end p 40
###begin title 41
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 63 70 <span type="species:ncbi:9606">patient</span>
Significance of the codon 72 status of the mutated TP53 on the patient outcome after postoperative chemotherapy
###end title 41
###begin p 42
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 329 334 329 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2a</xref>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2c</xref>
###xml 599 604 599 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 741 746 741 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2b, d</xref>
###xml 808 812 808 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 872 876 872 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 885 889 885 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3a</xref>
###xml 961 965 961 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1045 1049 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1128 1132 1128 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1164 1166 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3b</xref>
###xml 1205 1209 1205 1209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3c</xref>
###xml 1551 1555 1551 1555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1579 1581 1579 1581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3d</xref>
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 131 138 <span type="species:ncbi:9606">patient</span>
###xml 319 327 <span type="species:ncbi:9606">patients</span>
###xml 374 381 <span type="species:ncbi:9606">patient</span>
###xml 511 519 <span type="species:ncbi:9606">patients</span>
###xml 568 576 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 703 711 <span type="species:ncbi:9606">patients</span>
###xml 939 947 <span type="species:ncbi:9606">patients</span>
###xml 1019 1027 <span type="species:ncbi:9606">patients</span>
###xml 1179 1187 <span type="species:ncbi:9606">patients</span>
###xml 1219 1227 <span type="species:ncbi:9606">patients</span>
###xml 1525 1533 <span type="species:ncbi:9606">patients</span>
Fifty-four patients with TP53 mutation received postoperative chemotherapy, and there was no significant difference in the overall patient survival between the two codon 72 polymorphic status groups of the mutated alleles (n = 32 for R72 and n = 22 for P72) (p = 0.475; data not shown). Then, we focused on the stage C patients. TP53 mutation had no relation to the overall patient survival (Figure 2a). And there was no significant difference in the overall survival after postoperative chemotherapy among the patients without TP53 mutation (Figure 2c). However, all patients, or the patients with TP53 mutation, who received postoperative chemotherapy, showed a significantly better survival than the patients without chemotherapy (Figure 2b, d). Focusing on the codon 72 polymorphic status of the mutated TP53, survival after chemotherapy was not different between the TP53-R72 and TP53-P72 (Figure 3a). By contrast, as concerns the 16 patients with mutated TP53, who did not receive postoperative chemotherapy, the patients with the mutated TP53-R72 (n = 13) showed significantly longer survival than those with the mutated TP53-P72 (n = 3) (p = 0.012; Figure 3b). Among the patients with the mutated TP53-P72, the patients who received postoperative chemotherapy (n = 15) showed significantly better prognosis than those without chemotherapy (n = 3) (p = 0.012; Figure 3c). Although the tendency for a better prognosis was demonstrated by similar analysis, a statistically significant difference was not observed in the patients with the mutated TP53-R72 (p = 0.112; Figure 3d).
###end p 42
###begin p 43
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 0 92 0 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effect of chemotherapy and the <italic>TP53 </italic>mutation in colorectal cancer patients of Dukes' stage C</bold>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 369 374 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 483 488 483 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 237 245 <span type="species:ncbi:9606">patients</span>
###xml 333 341 <span type="species:ncbi:9606">Patients</span>
###xml 465 473 <span type="species:ncbi:9606">patients</span>
Effect of chemotherapy and the TP53 mutation in colorectal cancer patients of Dukes' stage C. (a): Overall survival of Dukes' stage C patients with the TP53 mutation and without the mutation (n = 62, P = 0.891). (b): Overall survival of patients with surgical treatment alone and with postoperative chemotherapy (n = 62, P = 0.037). Patients at Dukes' stage C with the TP53 mutation did not show significant sensitivity to chemotherapy (c) (n = 11, P = 0.727), but patients with the TP53 mutation show a significant effect of chemotherapy (d)(n = 51, P = 0.026).
###end p 43
###begin p 44
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 0 102 0 102 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effect of chemotherapy and the <italic>TP53 </italic>mutation on codon 72 polymorphic allele in Dukes' stage C patients</bold>
###xml 180 185 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 402 407 402 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
###xml 163 170 <span type="species:ncbi:9606">patient</span>
###xml 273 281 <span type="species:ncbi:9606">patients</span>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
Effect of chemotherapy and the TP53 mutation on codon 72 polymorphic allele in Dukes' stage C patients. (a): Overall survival of a Dukes' stage C and chemotherapy patient with the TP53 mutation of the Arg allele and Pro allele (n = 35, P = 0.368). (b): Overall survival of patients without chemotherapy and with TP53 mutation of the Arg and Pro allele (n = 16, P = 0.012). Dukes' stage C patients with TP53 mutation on the Pro allele show a significant effect of chemotherapy (c) (n = 18, P = 0.012), but the patients with mutation on the Arg allele did not reach statistical significance (d)(n = 33, P = 0.112).
###end p 44
###begin title 45
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 48 57 48 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 65 72 <span type="species:ncbi:9606">patient</span>
TP53 mutations showing effective p73 inhibition in vitro and the patient outcome
###end title 45
###begin p 46
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 152 160 <span type="species:ncbi:9606">patients</span>
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
We tested whether patients with 18 TP53 mutated allelotypes [24] demonstrate a poor prognosis or resistance to postoperative chemotherapy. Twenty-seven patients (5 in Dukes' stage A, 6 in stage B, 11 in stage C, and 5 in stage D) had such tumors. However, there were no statistical differences of survival when compared with the others overall, in each Dukes' stage, in patients that received chemotherapy or in patients without chemotherapy (data not shown).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 434 442 <span type="species:ncbi:9606">patients</span>
Although postoperative adjuvant therapy is accepted widely as the standard modality for stage III, Dukes' stage C or earlier stage CRC patients, Tang et al. reported that one-fourth of stage III patients and two-thirds of stage II patients received no such therapy [33]. Those patients tended to be older and to have less advanced tumors when compared with those who received postoperative adjuvant therapy. Therefore, predicting the patients who benefit from postoperative adjuvant therapy is important to selectively recommend the therapy and to improve the prognosis.
###end p 48
###begin p 49
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 519 523 519 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 707 712 707 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 960 965 960 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1109 1114 1109 1114 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1466 1470 1466 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 1505 1510 1505 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1554 1563 1554 1563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 1645 1650 1645 1650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1667 1672 1667 1672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 1714 1716 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 1913 1918 1913 1918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 625 633 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 1062 1070 <span type="species:ncbi:9606">patients</span>
###xml 1172 1180 <span type="species:ncbi:9606">patients</span>
###xml 1340 1348 <span type="species:ncbi:9606">patients</span>
###xml 1424 1432 <span type="species:ncbi:9606">patients</span>
###xml 1681 1686 <span type="species:ncbi:9606">human</span>
Although alterations of TP53 appear to have little- or no-prognostic significance for CRC patients treated with surgery alone [34], several clinical studies have demonstrated that CRC patients with wild-type TP53-tumors gain a survival benefit from 5-FU based postoperative chemotherapy, but those with TP53-mutated tumors do not [35-37]. Westra et al. also showed the same results from stage III colon cancer patients [35]. These studies were conducted in Australia, Europe and the United States. A large cohort, "the TP53-CRC-international collaborative study", which is a meta-analysis study analyzing more than 3,500 CRC patients from 17 countries, also demonstrated that Dukes' C tumors with wild-type TP53 showed a significantly better survival when treated with postoperative adjuvant chemotherapy [38]. This extensive meta-analysis, however, involved 2 Japanese studies with 103 CRC patients, corresponding to only 2.9% of all cases evaluated, and the TP53 mutation frequency ranged widely from 31% to 84%. In the present study, we included Japanese CRC patients from a single institute, and observed TP53 mutation in 70% of colorectal cancers. The Dukes' stage C patients who received postoperative chemotherapy showed a better overall survival than those who did not. This is consistent with previous investigations. However, the patients that benefited from the 5-FU based postoperative chemotherapy were not the patients with tumors containing wild-type TP53, but those with tumors containing TP53 mutation. Although Bunz et al. demonstrated in vitro that the apoptosis-inducing effect of 5-FU was almost abrogated when they deleted TP53 in the wild-type TP53 carrying human colon cancer cell, HCT116 [39], this situation is quite different from the actual clinical setting in which p53 function was knocked out not by homozygous deletion, but by missense mutation. Actually, we found that 72% of the TP53 alterations were missense mutation, which may result in gain-of-function oncogenic properties. Our results suggest that the oncogenic property of mutated p53 is involved significantly in the malignant phenotype of these tumors, and that the 5-FU based postoperative chemotherapy is effective.
###end p 49
###begin p 50
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 131 135 131 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 150 155 150 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53-</italic>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 253 257 253 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 692 696 692 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
Longley et al. reported that 5-FU increased Fas protein expression in the wild-type TP53 colon cancer HCT116 cells, but not in the TP53-null cells or TP53-mutated colon cancer H630 cells [40]. Our results showed that the tumors carrying the mutation on TP53-P72 benefited most from the 5-FU based postoperative chemotherapy seems contradictory to the results of those reports. However, it is unclear what TP53 mutation occurred in H630 and how the oncogenic property of p53 gain-of-function mutation in combination with R72P status influences the apoptosis system. Therefore, there may be unknown pathways of apoptosis that function preferentially in colorectal cancer cells with the mutated TP53-P72 in response to 5-FU based postoperative chemotherapy.
###end p 50
###begin p 51
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 491 500 491 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro </italic>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
Predicting which patients will benefit from the postoperative adjuvant therapy is important to improve CRC prognosis, and the prediction may be different when different adjuvant therapies are performed. In the present study, we identified CRC patients with tumors carrying TP53 mutation, especially on the codon 72 proline allele, as those patients that benefited most from 5-FU based postoperative chemotherapy. This result seems to be contradictory to several previous clinical reports or in vitro studies, but, we evaluated TP53 mutation by direct sequencing on fresh tumor samples and the precise discrimination of polymorphic status of the codon 72 were different from previous studies. The ethnic background of the investigated population may also be responsible for the differences.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 171 175 171 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
In the present study, we identified the codon 72 polymorphic status of the TP53 mutated allele in CRC patients. We found that Dukes' stage C CRC patients with the mutated TP53-R72 who did not receive postoperative chemotherapy showed significantly longer survival times than those with the mutated TP53-P72. Our results raised a possibility that Dukes' stage C CRC patients with tumors carrying TP53 mutation, especially the P72 allele, benefited most from 5-FU based postoperative chemotherapy, but we need to collect more CRC cases to form definite conclusions.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The authors declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
###xml 212 220 <span type="species:ncbi:9606">patients</span>
TG and TS performed the statistical analysis and drafted the manuscript. TG, TS, HS, AS and MY carried out sequencing and PCR analysis. TG, NS, KT, MS and MA collected and analyzed samples from colorectal cancer patients. YK performed pathological analysis and revised the manuscript. SM, YS, ET reviewed all data, and contributed to the preparation of the manuscript. YM directed the overall project, and participated in the editing of the final manuscript. All authors read and approved the final manuscript.
###end p 57
###begin title 58
Pre-publication history
###end title 58
###begin p 59
The pre-publication history for this paper can be accessed here:
###end p 59
###begin p 60

###end p 60
###begin title 61
Supplementary Material
###end title 61
###begin title 62
Additional file 1
###end title 62
###begin p 63
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Determination of the <italic>TP53 </italic>codon 72 polymorphic status of tumors</bold>
Determination of the TP53 codon 72 polymorphic status of tumors. The precise information for PCR conditions.
###end p 63
###begin p 64
Click here for file
###end p 64
###begin title 65
Additional file 2
###end title 65
###begin p 66
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Reverse primers used for mutant-allele-specific amplification</bold>
Reverse primers used for mutant-allele-specific amplification. The nucleotide sequences of the reverse primers, specific to each mutation site.
###end p 66
###begin p 67
Click here for file
###end p 67
###begin title 68
Additional file 3
###end title 68
###begin p 69
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Individual mutations in detail and the codon 72 allelism</bold>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
Individual mutations in detail and the codon 72 allelism. Precise information for the TP53 mutation found in each case was provided.
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Additional file 4
###end title 71
###begin p 72
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Location and frequency of p53 missense mutation in the p53 protein</bold>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 581 591 581 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hum Mutat </italic>
###xml 643 648 643 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
###xml 672 677 672 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53 </italic>
Location and frequency of p53 missense mutation in the p53 protein. The positions of the mutated amino acid of p53 and the number of mutations in exons 5-8 are shown by the black bar. One hundred and five tumors corresponded to transitions (58 G:A and 52 C:T) and 22 transversions (4 A:C, 1 A:T, 14 G:T, and 3 G:C) were identified. Four mutations identified in the present study (c.560-19_560-9del11, c.571-586del16, c.625_628delAGAA and c.673-16_673-4del13) have not been described in the 4 major databases for TP53 mutation: the IARC TP53 mutation database  [Petitjean A et al., Hum Mutat 2007], the database of germline p53 mutations , the TP53 knowledgebase , and the TP53 web site .
###end p 72
###begin p 73
Click here for file
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
This research was supported by grants from Kanagawa Cancer Research Fund. We thank Mr. Yoshiyasu Nakamura and Ms. Yukiko Yamazaki for their technical assistance. We thank Dr. Naoyuki Okamoto for his assistance with the statistical analyses.
###end p 75
###begin article-title 76
Isolation of p53-target genes and their functional analysis
###end article-title 76
###begin article-title 77
###xml 78 101 <span type="species:ncbi:333760">human papillomavirus 16</span>
p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein
###end article-title 77
###begin article-title 78
The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M
###end article-title 78
###begin article-title 79
A model for p53-induced apoptosis
###end article-title 79
###begin article-title 80
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
###end article-title 80
###begin article-title 81
A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
###end article-title 81
###begin article-title 82
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis
###end article-title 82
###begin article-title 83
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
###end article-title 83
###begin article-title 84
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
###end article-title 84
###begin article-title 85
p53 polymorphisms: cancer implications
###end article-title 85
###begin article-title 86
Recent advances in p53 research: an interdisciplinary perspective
###end article-title 86
###begin article-title 87
###xml 49 69 <span type="species:ncbi:10566">human papillomavirus</span>
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
###end article-title 87
###begin article-title 88
Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53
###end article-title 88
###begin article-title 89
Genetic polymorphisms of p53 and GSTP1, but not NAT2, are associated with susceptibility to squamous-cell carcinoma of the esophagus
###end article-title 89
###begin article-title 90
p53 polymorphisms and haplotypes in breast cancer
###end article-title 90
###begin article-title 91
p53 Codon 72 polymorphism and urothelial cancer risk
###end article-title 91
###begin article-title 92
Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina
###end article-title 92
###begin article-title 93
Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population
###end article-title 93
###begin article-title 94
P53 germ line haplotypes associated with increased risk for colorectal cancer
###end article-title 94
###begin article-title 95
Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer
###end article-title 95
###begin article-title 96
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
###end article-title 96
###begin article-title 97
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
###end article-title 97
###begin article-title 98
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
###end article-title 98
###begin article-title 99
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis
###end article-title 99
###begin article-title 100
Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer
###end article-title 100
###begin article-title 101
The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas
###end article-title 101
###begin article-title 102
TP53 mutation, allelism and survival in non-small cell lung cancer
###end article-title 102
###begin article-title 103
Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumors arising in Arg/Pro germline heterozygotes
###end article-title 103
###begin article-title 104
Mutagenically separated PCR (MS-PCR): a highly specific one step procedure for easy mutation detection
###end article-title 104
###begin article-title 105
Detection of K-ras mutation in sputum by mutant-allele-specific amplification (MASA)
###end article-title 105
###begin article-title 106
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy
###end article-title 106
###begin article-title 107
TP53 mutation in colorectal cancer
###end article-title 107
###begin article-title 108
###xml 174 182 <span type="species:ncbi:9606">patients</span>
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
###end article-title 108
###begin article-title 109
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection
###end article-title 109
###begin article-title 110
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study
###end article-title 110
###begin article-title 111
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment
###end article-title 111
###begin article-title 112
###xml 21 26 <span type="species:ncbi:9606">human</span>
Disruption of p53 in human cancer cells alters the responses to therapeutic agents
###end article-title 112
###begin article-title 113
The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites
###end article-title 113

